Blackridge's portfolio loads again, and you pick up where you left off: pharmaceutical companies. At first it looked like coincidence, an overexposure, a strategic tilt that hadn't corrected itself. The deeper you go, the less accidental it looks. The names repeat, not exactly but in pattern: large-cap drug manufacturers, vaccine developers, firms tied to oncology, to insulin, to long-term treatments that don't disappear once they're introduced. It isn't one or two positions. It's everywhere. Private equity firms don't move like this without a reason. Exposure of this scale isn't passive; it's a decision, a deliberate one, which means there's something you're missing. You open a new tab and search. News, then analysis, then commentary. You skim past the recycled opinions until a recent headline stands out, and open it. The article is straightforward. The government is preparing to increase NHS spending, significantly: capacity, long-term care, wider access to treatments that funding has held back until now. Alongside it, renewed talk of research grants and public money for pharmaceutical innovation, development pipelines, clinical trials. A careful, almost neutral section on lobbying makes the implication clear: large pharma firms have been positioning for this shift for a while, aligning themselves with policy before it's announced. Money is already moving. It just hasn't been acknowledged yet. You sit with it. Blackridge isn't reacting. Blackridge is anticipating. That's why the exposure feels so heavy, why it looks intentional: they're placing capital ahead of the wave, where they expect it to grow once the spending lands, once the grants release, once the market catches up to what's already in motion. It isn't a gamble. It's a timing decision. You wonder if there's more, and you'd like to find it. [[Return to portfolio]] --- [[Search the news]]